Is HRT right for me? a guided readiness check
Hot flashes, broken sleep, or vaginal symptoms may lead you to ask whether hormone therapy fits. No quiz or article can decide that. A clinician first checks for conditions that usually rule out systemic therapy, then weighs the symptom being treated, age and time since menopause, personal history, and treatment preferences.
The short version: Systemic hormone therapy may fit some people and be unsuitable for others. Listed contraindications can stop that pathway; when none applies, a clinician weighs symptom indication, age and timing, medical history, formulation, and personal priorities. This page prepares the conversation and does not diagnose suitability.
- Which history can rule out systemic hormone therapy
- How symptoms, age, and time since menopause shape the benefit-risk discussion
- Why systemic treatment and local GSM care follow different pathways
- What information to bring to an individual clinical assessment
Start with exclusions, then weigh symptoms and timing
The Menopause Society says the benefit-risk balance is generally favorable for most healthy, symptomatic women younger than 60 who are within 10 years of menopause onset. FDA's 2026 labeling update separately says clinicians should consider starting systemic therapy for moderate-to-severe hot flashes in women younger than 60 or within 10 years of menopause onset. Neither statement overrides a contraindication or replaces individual assessment. 2, 4
History comes first because unexplained vaginal bleeding, certain cancers, prior blood clot, stroke or heart attack, bleeding disorders, and liver disease usually rule out systemic therapy under FDA consumer guidance. When systemic therapy remains an option, symptoms, timing, route, and priorities shape the discussion. 5
Your history can change or stop the systemic pathway
A clinician will ask about your personal and family medical history because some conditions and risk factors change the picture. The goal is not to scare you off. It is to personalize the plan, choose the safest form if you proceed, and flag anything that calls for extra care.
What changed in 2026, and why people are asking now
FDA's February 2026 changes removed several statements from boxed warnings on six menopausal hormone-therapy products. The change did not make every product suitable for every patient or erase product-specific warnings and contraindications. Systemic estrogen-alone products retain the endometrial-cancer boxed warning. 1, 4
| Factor | What supports discussion | What changes or can stop the pathway |
|---|---|---|
| Symptoms | Hot flashes, night sweats, or vaginal dryness for which hormone therapy has an evidence-based role 6 | Symptoms with another likely cause or symptoms already managed by another approach |
| Age and timing | For many healthy, symptomatic women, younger than 60 and within 10 years of menopause onset 2 | Later initiation needs individualized review; timing does not override contraindications |
| History | No listed systemic exclusion after an individual review | Listed exclusions can rule out systemic therapy; see safety note. 5 |
FDA guidance says listed histories can rule out systemic therapy. Local GSM care follows a separate pathway: after estrogen-dependent breast cancer, ACOG recommends nonhormonal care first, then selected low-dose vaginal estrogen only after a risks-and-benefits discussion and shared decision-making when appropriate. 3, 5
How to get evaluated without being dismissed
This is also a fair standard to hold any provider to, online or in person. Before you hand over a card, a good women's health provider shows you the full cost up front: the consultation fee, the medication cost, any lab cost, and the cancellation policy, and no surprise charges later. If a brand cannot tell you all of those numbers plainly, that tells you something.
Prepare for an individual decision
No page can decide this for you, and that is a good thing. The decision deserves a clinician who knows your details and actually listens. Your job is to walk in ready. Now you are.
Explore your hormone therapy options
- Online evaluation by a licensed clinician
- Treatment based on your health and goals
- Clear pricing before you commit
From price shown is the 6-month plan rate. Prices may vary.
Frequently asked questions
Was this helpful?
Keep reading
Women's Health
Women's Health
Women's Health
Women's Health
Women's Health
Women's Health
Sources
- FDA. "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products." February 12, 2026. fda.gov
- The Menopause Society. ‘2022 Hormone Therapy Position Statement’ release. Accessed September 15, 2026. menopause.org
- ACOG. "Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer." December 2021. acog.org
- FDA. February 12, 2026 menopausal hormone-therapy labeling update. Product-specific retained warnings: fda.gov
- FDA. ‘Menopause: Medicines to Help You.’ Current page accessed September 15, 2026. fda.gov
- ACOG. ‘Hormone Therapy for Menopause.’ Current FAQ accessed September 15, 2026. acog.org